Response to 'NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors' by Xiang-Yu Meng
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/11/6/e007397.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850268536939741184 |
|---|---|
| author | David A Schoenfeld Jasmine I Caulfield Lilach Aizenbud Ana Luisa Perdigoto Matthew R Austin Jacqueline E Mann |
| author_facet | David A Schoenfeld Jasmine I Caulfield Lilach Aizenbud Ana Luisa Perdigoto Matthew R Austin Jacqueline E Mann |
| author_sort | David A Schoenfeld |
| collection | DOAJ |
| format | Article |
| id | doaj-art-a6c4ec238d9d477baf41234e7bdd151d |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-a6c4ec238d9d477baf41234e7bdd151d2025-08-20T01:53:26ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-06-0111610.1136/jitc-2023-007397Response to 'NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors' by Xiang-Yu MengDavid A Schoenfeld0Jasmine I Caulfield1Lilach Aizenbud2Ana Luisa Perdigoto3Matthew R Austin4Jacqueline E Mann51Yale University, New Haven, CT, USA1 Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USADepartment of Internal Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut, USA2 Department of Medicine (Endocrinology and Metabolism), Yale University School of Medicine, New Haven, Connecticut, USADepartment of Internal Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut, USADepartment of Internal Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut, USAhttps://jitc.bmj.com/content/11/6/e007397.full |
| spellingShingle | David A Schoenfeld Jasmine I Caulfield Lilach Aizenbud Ana Luisa Perdigoto Matthew R Austin Jacqueline E Mann Response to 'NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors' by Xiang-Yu Meng Journal for ImmunoTherapy of Cancer |
| title | Response to 'NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors' by Xiang-Yu Meng |
| title_full | Response to 'NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors' by Xiang-Yu Meng |
| title_fullStr | Response to 'NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors' by Xiang-Yu Meng |
| title_full_unstemmed | Response to 'NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors' by Xiang-Yu Meng |
| title_short | Response to 'NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors' by Xiang-Yu Meng |
| title_sort | response to nlrc5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors by xiang yu meng |
| url | https://jitc.bmj.com/content/11/6/e007397.full |
| work_keys_str_mv | AT davidaschoenfeld responsetonlrc5germlinevariantsandtheirpotentialroleinelicitinganimmuneresponseinpatientswithcancertreatedwithimmunecheckpointinhibitorsbyxiangyumeng AT jasmineicaulfield responsetonlrc5germlinevariantsandtheirpotentialroleinelicitinganimmuneresponseinpatientswithcancertreatedwithimmunecheckpointinhibitorsbyxiangyumeng AT lilachaizenbud responsetonlrc5germlinevariantsandtheirpotentialroleinelicitinganimmuneresponseinpatientswithcancertreatedwithimmunecheckpointinhibitorsbyxiangyumeng AT analuisaperdigoto responsetonlrc5germlinevariantsandtheirpotentialroleinelicitinganimmuneresponseinpatientswithcancertreatedwithimmunecheckpointinhibitorsbyxiangyumeng AT matthewraustin responsetonlrc5germlinevariantsandtheirpotentialroleinelicitinganimmuneresponseinpatientswithcancertreatedwithimmunecheckpointinhibitorsbyxiangyumeng AT jacquelineemann responsetonlrc5germlinevariantsandtheirpotentialroleinelicitinganimmuneresponseinpatientswithcancertreatedwithimmunecheckpointinhibitorsbyxiangyumeng |